Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in japan and the U.S.

Oncologist

Volumn 17, Issue 12, 2012, Pages 1547-1550

  Chihara, Dai ^a,b   Ito, Hidemi ^a   Matsuda, Tomohiro ^c   Katanoda, Kota ^c   Shibata, Akiko ^c   Saika, Kumiko ^c   Sobue, Tomotaka ^d   Matsuo, Keitaro ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic myelogenous leukemia; Imatinib; Japan; Mortality; SEER

Indexed keywords

IMATINIB;

AGE; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG SURVEILLANCE PROGRAM; GENDER; HUMAN; JAPAN; MORTALITY; PRIORITY JOURNAL; UNITED STATES;

BENZAMIDES; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; NATIONAL CANCER INSTITUTE (U.S.); PIPERAZINES; PYRIMIDINES; REGRESSION ANALYSIS; SEER PROGRAM; UNITED STATES;

EID: 84871566401     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0197     Document Type: Article

References (20)

1. Mangano DT, Rieves RD, Weiss KD. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-1317.
2. Hemminki E, Paakkulainen A. The effect of antibiotics on mortality from infectious diseases in Sweden and Finland. Am J Public Health 1976;66:1180-1184.
3. Edwardes EJ. A century of vaccination: Small-pox epidemics and small-pox mortality before and since vaccination came into use. Br Med J 1902;2:27-30.
4. Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-280.
5. Sant M, Allemani C, Tereanu C et al.; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood 2010;116:3724-3734.
6. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
7. Kantarjian H, O'Brien S, Jabbour E et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 2012;119:1981-1987.
8. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level. Haematologica 2008;93:1544-1549.
9. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
10. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
11. National Cancer Institute. Surveillance, Epidemiology, and End Results. US Population Data-1969-2009. Available at http://www.seer.cancer.gov/popdata, accessed November 7, 2011.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results. Available at http://www.seer. cancer.gov, accessed November 7, 2011.
13. Bray F, Guilloux A, Sankila R et al. Practical implications of imposing a new world standard population. Cancer Causes Control 2002;13:175-182.
14. Kim HJ, Fay MP, Feuer EJ et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351.
15. Nyström L, Andersson I, Bjurstam N et al. Longterm effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002;359: 909-919.
16. Lynge E, Madsen M, Engholm G. Effect of organized screening on incidence and mortality of cervical cancer in Denmark. Cancer Res 1989;49:2157-2160.
17. Matsuda T, Marugame T, Kamo K et al. Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012;42:139-147.
18. Jaffe E, Harris N, SteinHet al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer, 2001.
19. Strom SS, Yamamura Y, Kantarijian HM et al. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2009;18:1501-1506.
20. Björk J, Albin M, Welinder H et al. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med 2001;58:722-727.